Fulgent Genetics, Inc. (FLGT)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Ming Hsieh | Chairman & CEO | 2.13M | -- | 1956 |
| Mr. Jian Xie | COO & President | 838.29k | -- | 1966 |
| Mr. Paul Kim CPA | Chief Financial Officer | 853.64k | -- | 1967 |
| Dr. Hanlin Gao D.A.B.M.G., FACMG, M.D., Ph.D. | Chief Scientific Officer & Lab Director | 699.48k | -- | 1967 |
| Ms. Natalie Prescott | General Counsel & Chief Privacy Officer | -- | -- | -- |
| Ms. Doreen Ng | Vice President of Operations & Compliance | -- | -- | -- |
| Mr. Jakub Sram | Vice President of Business Development & Sales | -- | -- | -- |
| Ms. Ellen Tsui | Vice President of Human Resources | -- | -- | -- |
| Mr. Brandon Perthuis | Chief Commercial Officer | -- | -- | -- |
| Dr. Ray Yin | President & Chief Scientific Officer of Fulgent Pharma | -- | -- | -- |
Fulgent Genetics, Inc.
- Sector:
- Healthcare
- Industry: Diagnostics & Research
- Full Time Employees:
- 1,313
Description
Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. The company was founded in 2011 and is headquartered in El Monte, California.
Corporate Governance
Upcoming Events
May 2, 2025 at 12:30 PM UTC
Fulgent Genetics, Inc. Earnings Date
Recent Events
February 7, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission